Aprea Therapeutics Inc (APRE)
1.67
+0.01
(+0.60%)
USD |
NASDAQ |
May 23, 16:00
1.64
-0.03
(-1.80%)
Pre-Market: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 9.237M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -66.75% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.5941 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.95% |
Profile
Edit
| Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. |
| URL | https://www.aprea.com |
| Investor Relations URL | https://ir.aprea.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 12, 2025 (est.) |
| Last Earnings Release | May. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. |
| URL | https://www.aprea.com |
| Investor Relations URL | https://ir.aprea.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 12, 2025 (est.) |
| Last Earnings Release | May. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |